التفاصيل البيبلوغرافية
| العنوان: |
A chance to cut is a chance to cure: complete resection of an atypical neurofibroma prevents further progression to malignancy. |
| المؤلفون: |
Vaassen, Pia, Feldkamp, Axel, Scholz, Martin, Blau, Tobias, Dürr, Nikola Reinhard, Rosenbaum, Thorsten |
| المصدر: |
Child's Nervous System; Nov2023, Vol. 39 Issue 11, p3301-3304, 4p |
| مصطلحات موضوعية: |
NEUROFIBROMA, SURGICAL excision, NEUROFIBROMATOSIS 1, TUMOR treatment |
| مستخلص: |
Plexiform neurofibromas are the hallmark of neurofibromatosis type 1 (NF1) and significantly contribute to the overall burden of disease. While surgical excision has long been the only available therapy, the MEK inhibitor (MEKi) selumetinib has been approved as a non-surgical treatment option for these tumors in 2020 (USA) and 2021 (Europe), respectively. However, selumetinib will result in tumor shrinkage only after several months of therapy and might not prevent malignant transformation of a plexiform neurofibroma that occurs with a frequency of 10–15%. Here, we demonstrate that surgical excision might be the therapy of choice in some plexiform neurofibromas despite the availability of MEKi therapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Child's Nervous System is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
